A total of 94 clinical isolates of the Bacteroides fragilis group was tested for susceptibility to metronidazole, chloramphenicol, clindamycin, cefoxitin, cefotetan, cefmetazole, moxalactam, mezlocillin, amoxicllin-clavulanic acid, and imipenem. All the strains tested were susceptible to imipenem, metronidazole, amoxicillinclavulanic acid, and chloramphenicol. The rate of resistance to clindamycin was 21%. The results of this study demonstrate a difference in resistance rates from one species of the B. fragilis group to another.
and Edmiston et al. (13) . Cefmetazole displayed poor activity for the non-B. fragilis species included in the B. fragilis group.
B. fragilis tended to be much more susceptible to the cephamycins than the other members of the group (Table 2) .
The results of this study indicate that several of the new beta-lactam agents are effective in vitro against the B. fragilis group. As expected, chloramphenicol and metronidazole were uniformly effective against all 94 isolates. Imipenem was the most effective beta-lactam drug in this study; the MIC for 90% of the strains was 0.5 ,ug/ml, and we detected no resistance, which was in accordance with the ANTIMICROB. AGENTS CHEMOTHER. literature, in which only occasional resistant strains of B. fragilis have been reported (6, 17) . The combination of clavulanic acid and amoxicillin showed good activity against B. fragilis and other B. fragilis group strains. Our results are similar to the data reported by others (3, 5, 15) .
The incidence of clindamycin resistance in the B. fragilis group has been reported by several investigators (1, 8, 20, 22) , although there is considerable variation in the resistance rates observed in different surveys, ranging from very low (0.6%, Bourgault et al. [2] ) to moderate (7%, Tally et al. [24] , and 10%, Derriennic et al. [10] ) to high resistance rates similar to ours (about 20% clindamycin resistance [1, 9, 19, 21] ).
This study confirms the reports of other investigators (3, 8, 16, 26) regarding the variation of susceptibility patterns among the species of the B. fragilis group, particularly with susceptibility to the beta-lactam agents. Souza Dias et al. (23) observed that the high resistance level was not limited to indole-positive strains, as suggested by Jenkins et al. (16) , but was also present in B. distasonis. Of the various species in the group, B. fragilis is the most susceptible to the cephamycins; the species with lowest susceptibility to cephamycins were B. thetaiotaomicron, B. ovatus, and B. distasonis.
These data emphasize the need to identify species in the B. fragilis group and to determine the susceptibility patterns in order to facilitate the selection of adequate antimicrobial therapy.
Because of the increasing resistance of anaerobic bacteria to antimicrobial agents and because of regional differences in resistance patterns (1, 2, 7, 11, 24), we conclude that clinical microbiology laboratories should perform periodic suscepti- bility studies on anaerobic bacteria in order to detect changes in susceptibility profiles, to determine patterns of susceptibility of anaerobes to new antimicrobial agents, and to guide the choice of agents for the treatment of infections caused by anaerobic bacteria.
